Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Yahoo Finance5d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk ... thought would take over the industry, Novo Nordisk's ...
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...